Physician profile
Jared Luke
NPI 1366900607
$11,813.10
in general payments reported to CMS, 2019-2025
29 companies · $3,395 in 2025
The $3,395 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $827 · 2022: $2,162 · 2023: $2,360 · 2024: $3,070 · 2025: $3,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,730 · Education: $94.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,730.11 |
| Education | $94.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,095.23 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $2,040.52 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,320.24 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $769.50 | 2021-2025 | |
| Genzyme Corporation | $707.42 | 2021-2025 | |
| Leo Pharma INC. | $691.63 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Lilly USA, LLC | $653.14 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $633.99 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $592.20 | 2022-2025 | Bimzelx |
| Incyte Corporation | $375.63 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $332.27 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $296.77 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $162.69 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $158.70 | 2022-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $154.99 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $147.26 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $126.27 | 2023-2025 | Zoryve |
| Organon LLC | $123.20 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.43 | 2024-2025 | Cabtreo |
| Janssen Scientific Affairs, LLC | $69.30 | 2022 | |
| Organogenesis INC. | $63.05 | 2023 | Puraply |
| Botanix Sb INC | $43.88 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $31.90 | 2025 | Natroba, Spinosad |
| Paratek Pharmaceuticals, INC. | $23.81 | 2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.30 | 2022 | |
| Epi Health, LLC | $21.99 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.10 | 2024 | Ycanth |
| Chiesi USA, INC. | $17.01 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $14.68 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.